Rhenman Partners Asset Management Ab buys $5,993,000 stake in Lion Biotechnologies Inc (LBIO)

Lion Biotechnologies Inc (LBIO) : Rhenman Partners Asset Management Ab scooped up 50,000 additional shares in Lion Biotechnologies Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 650,000 shares of Lion Biotechnologies Inc which is valued at $5,993,000.Lion Biotechnologies Inc makes up approximately 0.96% of Rhenman Partners Asset Management Ab’s portfolio.

Other Hedge Funds, Including , California State Teachers Retirement System boosted its stake in LBIO in the latest quarter, The investment management firm added 69 additional shares and now holds a total of 95,464 shares of Lion Biotechnologies Inc which is valued at $880,178.Rs Investment Management Co reduced its stake in LBIO by selling 479,913 shares or 17.81% in the most recent quarter. The Hedge Fund company now holds 2,214,585 shares of LBIO which is valued at $19,178,306. Lion Biotechnologies Inc makes up approx 0.19% of Rs Investment Management Co’s portfolio. Trust Co Of Vermont sold out all of its stake in LBIO during the most recent quarter. The investment firm sold 2,000 shares of LBIO which is valued $16,400.Creative Planning boosted its stake in LBIO in the latest quarter, The investment management firm added 350 additional shares and now holds a total of 1,000 shares of Lion Biotechnologies Inc which is valued at $8,340. Bnp Paribas Arbitrage Sa added LBIO to its portfolio by purchasing 1,762 company shares during the most recent quarter which is valued at $15,224.

Lion Biotechnologies Inc closed down -0.16 points or -1.74% at $9.06 with 2,90,926 shares getting traded on Thursday. Post opening the session at $9.22, the shares hit an intraday low of $9.03 and an intraday high of $9.22 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

Lion Biotechnologies Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing adoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TILs) for the treatment of metastatic melanoma and other solid cancers. The Company’s program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) which are T cells derived from patients’ tumors for the treatment of metastatic melanoma. Once the TILs have been multiplied to a sufficient number ex vivo and after the patient has completed the non-myeloablative chemotherapeutic regimen the TILs are infused into the patient along with a high dose of interleukin2 (IL2) a protein that stimulates the immune system.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *